Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9610844 | 0.78 | EPHX2 (0.38) | PAOXANPEP | |
| SCHEMBL27330238 | 0.75 | — | — | |
| SCHEMBL13130742 | 0.74 | DPP4 (0.30) | — | |
| SCHEMBL10060469 | 0.73 | ALDH1A1 (0.30) | — | |
| SCHEMBL23695749 | 0.73 | MEN1 (0.36) | — | |
| SCHEMBL23729794 | 0.73 | BCHE (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL13880841 | 0.73 | PAOX (0.39) | PAOXANPEPCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL10165857 | 0.72 | — | — | |
| SCHEMBL23560102 | 0.70 | MEN1 (0.42) | — | |
| SCHEMBL21472752 | 0.70 | MEN1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20190343828-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | PAOX 3541/4885ANPEP 1261/4885CHRNB2 3199/4885 |
| US-20190343828-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | VIP, DCLRE1A, UACA | PAOX 2394/4885ANPEP 358/4885CHRNB2 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.